Agios Pharmaceuticals Inc
AGIO
Market Cap$1.72B
Close$
$-8.61
129.7% downside
Current Fair Value
129.7% downsideOvervalued by 129.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.72 Billion |
|---|---|
| Enterprise Value | $455.60 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $24.93 |
| Beta | 1.04 |
| Outstanding Shares | 56,194,847 |
| Avg 30 Day Volume | 640,984 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 1.07 |
|---|---|
| PEG | -10.41 |
| Price to Sales | - |
| Price to Book Ratio | 1.21 |
| Enterprise Value to Revenue | 10.34 |
| Enterprise Value to EBIT | -1.24 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Agios Pharmaceuticals Inc
536 employees
CEO: Jacqualyn Fouse Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation b...